Skip to main content

DeCode s Shares Rebound After Mid-day Dip Following Positive Drug Data

This article has been updated from a previous version. Share prices have been updated.


NEW YORK, Oct. 19 (GenomeWeb News) - Shares in DeCode Genetics closed up more than11 percent at $7.36 yesterday, regaining lost ground after the stock dipped mid-day following after the Icelandic pharmacogenomics company announced positive results from an ongoing drug trial.


Shares in the Icelandic pharmacogenomics company were at $7.31 in early-morning trading on the Nasdaq exchange today. They reached a high of $7.70 yesterday, but  receded to $6.90 in afternoon trade.


DeCode licensed the drug, which is in early-stage Phase IIa clinical testing, from  Bayer last November

Results of the study showed the drug, called DG031, to have significantly reduced levels of two chemical biomarkers associated with arterial inflammation and myocardial infarction risk.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.